SCHEMBL3886447

SCHEMBL3886447

O[SiH](O)CCC1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
SIGMAR1 Q99720 3/20 0.39
HPGD P15428 1/20 0.38
CYP2D6 P10635 1/20 0.36
METAP1 P53582 1/20 0.36
EPHX1 P07099 1/20 0.35
DAO P14920 1/20 0.32
CHRM5 P08912 2/20 0.32
ADRA2C P18825 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM1 P11229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4536247 0.75 PLG (0.32)
SCHEMBL8107616 0.74 CYP1A2 (0.42) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL26104278 0.74 CYP1A2 (0.48) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL5617552 0.73 CYP1A2 (0.58) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL6077957 0.73 CYP1A2 (0.58) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL6524230 0.73 CYP1A2 (0.58) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL1524766 0.73 CYP1A2 (0.58) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL11407095 0.73 CYP1A2 (0.58) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL6518887 0.73 CYP1A2 (0.58) CYP1A2SIGMAR1HPGDMETAP1EPHX1
SCHEMBL2573209 0.73 CYP1A2 (0.58) CYP1A2SIGMAR1HPGDMETAP1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9884879-B2 Method of synthesizing siloxane monomers and use thereof SILECS OY (FI) 2018-02-06 US claimed
US-20170088565-A1 Method of synthesizing siloxane monomers and use thereof SILECS OY (FI) 2017-03-30 US claimed
US-20140249326-A1 Method of Synthesizing Siloxane Monomers and Use Thereof SILECS OY (FI) 2014-09-04 US claimed
WO-2012172176-A9 METHOD OF SYNTHESIZING SILOXANE MONOMERS AND USE THEREOF SILECS OY (FI) 2013-02-07 WO claimed
WO-2012172176-A2 METHOD OF SYNTHESIZING SILOXANE MONOMERS AND USE THEREOF SILECS OY (FI) 2012-12-20 WO claimed
US-9884879-B2 Method of synthesizing siloxane monomers and use thereof SILECS OY (FI) 2018-02-06 US disclosed
US-20170088565-A1 Method of synthesizing siloxane monomers and use thereof SILECS OY (FI) 2017-03-30 US disclosed
US-9458183-B2 Method of synthesizing siloxane monomers and use thereof SILECS OY (FI) 2016-10-04 US disclosed
US-20140249326-A1 Method of Synthesizing Siloxane Monomers and Use Thereof SILECS OY (FI) 2014-09-04 US disclosed
WO-2012172176-A9 METHOD OF SYNTHESIZING SILOXANE MONOMERS AND USE THEREOF SILECS OY (FI) 2013-02-07 WO disclosed
WO-2012172176-A2 METHOD OF SYNTHESIZING SILOXANE MONOMERS AND USE THEREOF SILECS OY (FI) 2012-12-20 WO disclosed
US-7572303-B2 A symmetrical dialkyl carbonate, a metal, borong, silicon, or group 7 compound, a hydrogen or hydrocarbon-based fuel, an oxidizer, and a metallic cocatalyst; minimized hydrolysis; improved combustion and storage stability OCTANE INTERNATIONAL, LTD. (US) 2009-08-11 US disclosed
EP-0954558-B1 FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY ORR WILLIAM C (US) 2006-06-14 EP disclosed
US-20050044778-A1 Fuel compositions employing catalyst combustion structure OCTANE INTERNATIONAL, LTD. 2005-03-03 US disclosed
US-20040237384-A1 Fuel compositions exhibiting improved fuel stability OCTANE INTERNATIONAL, LTD. 2004-12-02 US disclosed
US-6652608-B1 Fuel compositions exhibiting improved fuel stability OCTANE INTERNATIONAL, LTD. 2003-11-25 US disclosed
EP-1051461-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR, William C. (US) 2000-11-15 EP disclosed
WO-1999066009-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR WILLIAM C (US) 1999-12-23 WO disclosed
EP-0954558-A1 FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY ORR, William C. (US) 1999-11-10 EP disclosed
WO-1998026028-A1 FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY ORR WILLIAM C (US) 1998-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170088565-A1 Method of synthesizing siloxane monomers and use thereof MSMO1, PCNA, PIEZO1 CYP1A2 421/4885SIGMAR1 338/4885HPGD 2843/4885
US-20140249326-A1 Method of Synthesizing Siloxane Monomers and Use Thereof MSMO1, PCNA, PIEZO1 CYP1A2 421/4885SIGMAR1 338/4885HPGD 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.